BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Idenix Pharmaceuticals, Inc. 

Corporate Headquarters
60 Hampshire Street
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-995-9800 Fax: 617-995-9801


SEARCH JOBS
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. Idenix is advancing a robust product pipeline in HCV treatment with programs in four different HCV drug classes. The company’s clinical candidates include IDX184, a liver-targeted nucleotide polymerase inhibitor, IDX320, a protease inhibitor and IDX375, a non-nucleoside polymerase inhibitor. Idenix also has a preclinical NS5A inhibitor program. Idenix believes that the future of HCV treatment will include novel combinations of direct-acting antivirals (DAAs) which could eliminate the need for interferon and/or ribavirin. The company’s goal is to develop low dose, once- or twice-daily agents with broad genotypic activity, a low potential for drug-drug interaction and that are designed for use in multiple combination regimens. With programs that span the major HCV drug classes, Idenix is well positioned to build a combination drug development strategy, both internally and with partners, to advance the future HCV paradigm.

 Key Statistics


Email:
Ownership: Public

Web Site: Idenix Pharmaceuticals, Inc.
Employees: 200 + worldwide
Symbol: IDIX
 









 Company News
Idenix Pharmaceuticals, Inc. (IDIX)'s "Good" News Shows Hep C Drug Market Increasingly Murky For Investors 4/9/2014 6:05:01 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Announces Promising Clinical Data And Continued Progress In Nucleotide Prodrug Development Programs For The Treatment Of Hepatitis C 4/7/2014 9:29:00 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Intends To Appeal Norway District Court Decision Regarding Patent Invalidity Case 3/24/2014 9:04:29 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Announces Nucleotide Prodrug (IDX21437) And NS5A Inhibitor (Samatasvir) Poster Presentations At 49th Annual Meeting Of The European Association For The Study Of The Liver 3/24/2014 8:53:52 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Files Patent Infringement Lawsuits Against Gilead Sciences, Inc. (GILD) In Europe 3/14/2014 9:27:24 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Reports Fourth Quarter And Year Ended 2013 Financial Results 2/28/2014 9:24:24 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) To Present At Two Upcoming Healthcare Conferences 2/26/2014 9:03:57 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) To Present At The 2014 Leerink Swann and Company Global Healthcare Conference 2/7/2014 9:06:12 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Announces Decision By The United States Patent And Trademark Office Patent Trial And Appeal Board In The First Patent Interference 1/30/2014 8:54:47 AM    More...
Idenix Pharmaceuticals, Inc. (IDIX) Eyes $106.7 Million Through Registered Direct Offering 1/28/2014 7:39:52 AM    More...
12345678910...

//-->